Indian drugmaker Biocon (BSE: 532523) closed more than 5% down at 628.65 rupees after trading on Mumbai on Thursday.
The reason behind this dip was the company’s update on the regulatory inspections that have revealed issues at its manufacturing plant in Bangalore.
In a statement, Biocon revealed that the US Food and Drug Administration (FDA) had completed a pre-approval inspection of the sterile drug product manufacturing facility this week and issued a Form 483 with seven observations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze